BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 35 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $240,000 | +22.4% | 55,241 | 0.0% | 0.01% | +11.1% |
Q4 2018 | $196,000 | -7.1% | 55,241 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $211,000 | -1.9% | 55,241 | 0.0% | 0.01% | -10.0% |
Q2 2018 | $215,000 | +74.8% | 55,241 | +41.2% | 0.01% | +100.0% |
Q1 2018 | $123,000 | -19.6% | 39,115 | 0.0% | 0.01% | -28.6% |
Q4 2017 | $153,000 | -5.0% | 39,115 | 0.0% | 0.01% | 0.0% |
Q3 2017 | $161,000 | -0.6% | 39,115 | 0.0% | 0.01% | 0.0% |
Q2 2017 | $162,000 | -2.4% | 39,115 | 0.0% | 0.01% | 0.0% |
Q1 2017 | $166,000 | +66.0% | 39,115 | -0.2% | 0.01% | +75.0% |
Q4 2016 | $100,000 | +6.4% | 39,203 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $94,000 | +70.9% | 39,203 | +72.6% | 0.00% | +100.0% |
Q2 2016 | $55,000 | -9.8% | 22,715 | 0.0% | 0.00% | -33.3% |
Q1 2016 | $61,000 | +96.8% | 22,715 | +112.0% | 0.00% | +200.0% |
Q4 2015 | $31,000 | +24.0% | 10,715 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $25,000 | -35.9% | 10,715 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $39,000 | -18.8% | 10,715 | 0.0% | 0.00% | -50.0% |
Q1 2015 | $48,000 | – | 10,715 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 189,935 | $311,494 | 0.08% |
ABNER HERRMAN & BROCK LLC | 280,000 | $459 | 0.07% |
Weaver Consulting Group | 65,947 | $108,153 | 0.06% |
S.C. Financial Services, Inc. | 25,372 | $41,610 | 0.03% |
JMAC ENTERPRISES LLC | 40,430 | $66,305 | 0.02% |
Weaver Consulting Group | 53,500 | $10,047 | 0.01% |
IFP Advisors, Inc | 26,650 | $139 | 0.00% |
Bangor Savings Bank | 4,000 | $7 | 0.00% |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $4,920 | 0.00% |
BOOTHBAY FUND MANAGEMENT, LLC | 19,098 | $31,321 | 0.00% |